|
Clinical features associated with systemic sclerosis autoantibodies |
||||||
| Antibodies |
||||||
|
|
||||||
| ACA |
Th/To |
U1RNP |
U3RNP |
Topo |
Pol III |
|
|
|
||||||
| Patient characteristics |
Female |
MCTD |
African American |
|||
| Disease subtype |
Limited |
Limited |
Limited |
Diffuse |
Diffuse |
Diffuse |
| Joint/skin involvement |
↓ Joint |
↓ Joint |
↑ Joint |
↑↑ Skin |
||
| Muscle involvement |
↑ |
↑ |
||||
| Calcinosis |
↑ |
|||||
| Acroosteolysis |
↑ |
↑ |
||||
| DUs |
Yes |
Yes |
||||
| PAH ± PF |
PAH |
PAH |
PAH |
PAH + PF |
PF |
↓↓ PF |
| Renal crisis |
Yes |
Yes |
↑ |
|||
|
ACA, anticentromere antibodies; DU, digital ulcer; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; PF, pulmonary fibrosis; Pol III, polymerase III; Topo, topoisomerase; U1RNP, U1 ribonuclear protein; U3RNP, U3 ribonuclear protein. | ||||||
Matucci-Cerinic et al. Arthritis Research & Therapy 2007 9(Suppl 2):S7 doi:10.1186/ar2191 |
||||||